MeSH term
Frequency | Condition_Probility | Humans | 45 | 0.0 |
Animals | 25 | 0.0 |
Binding Sites/genetics | 2 | 0.0 |
Antigens, Thy-1/genetics | 2 | 40.0 |
Kinetics | 3 | 0.0 |
Mice | 16 | 0.0 |
Mice, Transgenic | 3 | 0.0 |
Brain/metabolism/pathology | 2 | 1.0 |
Disease Models, Animal | 3 | 0.0 |
Mice, Inbred C57BL | 5 | 0.0 |
Research Support, Non-U.S. Gov't | 34 | 0.0 |
Antigens, CD34/*analysis | 2 | 0.0 |
Colony-Forming Units Assay | 3 | 0.0 |
*Gene Transfer Techniques | 2 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 22 | 0.0 |
Transfection | 2 | 0.0 |
Chromosome Mapping | 12 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 8 | 0.0 |
Adult | 6 | 0.0 |
Aged | 2 | 0.0 |
Female | 14 | 0.0 |
Granulocyte Colony-Stimulating Factor/pharmacology | 2 | 1.0 |
Male | 13 | 0.0 |
Middle Aged | 5 | 0.0 |
Chromosome Aberrations | 2 | 0.0 |
Cloning, Molecular | 2 | 0.0 |
DNA Primers | 3 | 0.0 |
Genetic Vectors | 2 | 0.0 |
In Situ Hybridization, Fluorescence | 2 | 0.0 |
Molecular Sequence Data | 6 | 0.0 |
Nucleic Acid Hybridization | 3 | 0.0 |
Polymerase Chain Reaction | 4 | 0.0 |
Tumor Cells, Cultured | 5 | 0.0 |
Cell Count | 3 | 0.0 |
Comparative Study | 3 | 0.0 |
Dose-Response Relationship, Drug | 2 | 0.0 |
Rats | 3 | 0.0 |
Time Factors | 3 | 0.0 |
Immunohistochemistry | 3 | 0.0 |
Blotting, Northern | 2 | 0.0 |
Cell Division | 5 | 0.0 |
Flow Cytometry | 4 | 0.0 |
Immunoenzyme Techniques | 2 | 0.0 |
Mice, SCID | 2 | 0.0 |
RNA, Messenger/genetics/metabolism | 2 | 0.0 |
Antineoplastic Agents/*pharmacology | 2 | 0.0 |
Gamma Rays | 2 | 0.0 |
Base Sequence | 6 | 0.0 |
Cells, Cultured | 6 | 0.0 |
Recombinant Proteins/pharmacology | 2 | 0.0 |
Cell Adhesion Molecules, Neuronal/genetics | 3 | 21.0 |
*Chromosome Mapping | 3 | 0.0 |
*Chromosomes, Human, Pair 11 | 9 | 1.0 |
Hybrid Cells | 4 | 0.0 |
Species Specificity | 2 | 0.0 |
Cell Line | 6 | 0.0 |
Antigens, Surface/genetics | 4 | 8.0 |
Antigens, Thy-1 | 5 | 17.0 |
Blotting, Southern | 5 | 0.0 |
DNA Probes | 7 | 0.0 |
DNA, Neoplasm/analysis | 2 | 0.0 |
Hydroxymethylbilane Synthase/genetics | 2 | 12.0 |
Leukemia/*genetics | 3 | 2.0 |
Adolescent | 3 | 0.0 |
Child | 5 | 0.0 |
Child, Preschool | 4 | 0.0 |
Infant | 2 | 0.0 |
Translocation, Genetic | 2 | 0.0 |
Ataxia Telangiectasia/*genetics | 5 | 7.0 |
*Chromosomes, Human, Pair 11/ultrastructure | 3 | 60.0 |
Genetic Markers | 5 | 0.0 |
Likelihood Functions | 2 | 1.0 |
Chromosomes, Human, Pair 11 | 3 | 0.0 |
Cosmids | 2 | 0.0 |
Alleles | 2 | 0.0 |
Japan | 2 | 0.0 |
Polymorphism, Restriction Fragment Length | 3 | 0.0 |
In Vitro | 2 | 0.0 |
Pedigree | 3 | 0.0 |
Antigens, CD3 | 2 | 0.0 |
Antigens, Differentiation, T-Lymphocyte/*genetics | 2 | 3.0 |
Leukemia, Lymphocytic, Acute/*genetics | 2 | 2.0 |
Restriction Mapping | 2 | 0.0 |
*Translocation, Genetic | 3 | 0.0 |
Genes, Structural | 2 | 0.0 |
Models, Genetic | 2 | 0.0 |
Proto-Oncogene Proteins/genetics | 2 | 0.0 |
*Transcription Factors | 2 | 0.0 |
Chromosome Banding | 4 | 0.0 |
Karyotyping | 2 | 0.0 |
Linkage (Genetics) | 3 | 0.0 |
Receptors, Antigen, T-Cell/genetics | 2 | 2.0 |
*Genetic Markers | 3 | 0.0 |
Antigens, CD34/biosynthesis | 2 | 2.0 |
